Compare BridgeBio Pharma Inc (BBIO) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Enphase Energy Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Enphase Energy Inc trades at $42.32 (market cap $5.41B). The key difference: BridgeBio Pharma Inc is far larger — about 3.1× Enphase Energy Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | ENPH | |
|---|---|---|
Market Cap | $16.61B | $5.41B |
Sector | Health | Technology |
52-Week High | $90.17 | $72.33 |
52-Week Low | $47.29 | $26.12 |
Enterprise Value | $18.16B | $5.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Enphase Energy (ENPH) trades at $41.87, up 5.55% with bullish technical signals and mixed quarterly earnings. The company reported Q2 2026 EPS of $0.46, missing expectations, while revenue declined 19.6% year-over-year. Recent product expansions in battery systems and U.S. manufacturing commitments provide growth catalysts, though residential solar demand remains volatile. Valuation metrics show a P/E of 41.46 and P/S of 4.2, reflecting premium pricing amid earnings normalization.
Outlook remains cautiously optimistic with analyst consensus price target of $45.37 offering 8% upside potential. Key opportunities include European storage growth and AI data center initiatives, while risks center on U.S. demand weakness and competitive pressures. The stock faces near-term resistance at $43-$45 levels with institutional ownership showing mixed positioning through recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
